{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:34:37Z","timestamp":1787502877668,"version":"build-2736575974"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Clinically silent corticotroph tumors are usually macroadenomas that comprise 20% of ACTH tumors. They frequently progress to aggressive tumors with high recurrence, invasiveness, and on rare occasions, they may become hormonally active causing Cushing\u2019s disease. Trustable biomarkers that can predict their aggressive course, as well as their response to traditional or new therapies, are paramount. Aberrant \u03b2-Catenin expression and localization have been proposed as responsible for several malignancies including pituitary tumors. Nevertheless, the role of \u03b2-Catenin in the aggressive transformation of silent corticotropinomas and their response to Temozolomide salvage treatment have not been explored yet. In this work, we present a case of a silent corticotroph tumor that invaded cavernous sinus and compressed optic chiasm and, after a first total resection and tumor remission it recurred six years later as an aggressive ACTH-secreting tumor. This lesion grew with carotid compromise and caused Cushing\u2019s signs. It required multiple medical treatments including Cabergoline, Ketoconazole, TMZ, and radiotherapy. Besides, other two surgeries were needed until it could be controlled. Interestingly, we found \u03b1-SMA vascular area reduction and differential \u03b2-Catenin cell localization in the more aggressive tumor stages characterized by high Ki-67 indexes and p53 expression. Our results may indicate a role of angiogenesis and \u03b2-Catenin trigged events in the pituitary tumor progression, which could in turn affect the response to TMZ and\/or conventional treatments. These molecular findings in this unusual case could be useful for future management of aggressive pituitary tumors.<\/jats:p>","DOI":"10.3389\/fendo.2022.870172","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T04:15:47Z","timestamp":1658204147000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case Report: Progression of a Silent Corticotroph Tumor to an Aggressive Secreting Corticotroph Tumor, Treated by Temozolomide. Changes in the Clinic, the Pathology, and the \u03b2-Catenin and \u03b1-SMA Expression"],"prefix":"10.3389","volume":"13","author":[{"given":"Gianina","family":"Demarchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sof\u00eda","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaela","family":"Esper Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"De Bonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Casasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Sevlever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Ines","family":"Berner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Cristina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-19-0046","article-title":"Postoperative Expression of Cushing Disease in a Young Male: Metamorphosis of Silent Corticotroph Adenoma","volume":"2019","author":"Jahan","year":"2019","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-66-6-1111","article-title":"A Novel Type of Pituitary Adenoma: Morphological Features and Clinical Correlations","volume":"66","author":"Horvath","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-018-0864-8","article-title":"Silent Corticotroph Adenomas","volume":"21","author":"Ben-Shlomo","year":"2018","journal-title":"Pituitary"},{"key":"B4","article-title":"Clinically Nonfunctioning Pituitary Adenomas","volume-title":"Diagnosis and Management of Pituitary Tumors","author":"Young","year":"2001"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-014-0624-3","article-title":"Silent Corticotroph Adenomas","volume":"18","author":"Cooper","year":"2015","journal-title":"Pituitary"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00701-012-1378-1","article-title":"Clinical Features of Silent Corticotroph Adenomas","volume":"154","author":"Alahmadi","year":"2012","journal-title":"Acta Neurochir"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1227\/00006123-200009000-00039","article-title":"Clinically Silent Corticotroph Tumors of the Pituitary Gland","volume":"47","author":"Scheithauer","year":"2000","journal-title":"Neurosurgery"},{"key":"B8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1530\/EJE-10-0076","article-title":"Clinical, Hormonal and Molecular Characterization of Pituitary ACTH Adenomas Without (Silent Corticotroph Adenomas) and With Cushing's Disease","volume":"163","author":"Raverot","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2014.07.013","article-title":"Silent Corticotroph Adenomas After Stereotactic Radiosurgery: A Case-Control Study","volume":"90","author":"Xu","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.5137\/1019-5149.JTN.9629-13.1","article-title":"Pituitary Atypical Adenoma or Carcinoma Sensitive to Temozolomide Combined With Radiation Therapy: A Case Report of Early Identification and Management","volume":"24","author":"Zhong","year":"2014","journal-title":"Turkish Neurosurg"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-016-0721-6","article-title":"Radiotherapy With Concurrent Temozolomide for the Management of Extraneural Metastases in Pituitary Carcinoma","volume":"19","author":"Kamiya-Matsuoka","year":"2016","journal-title":"Pituitary"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.05.016","article-title":"Wnt\/beta-Catenin Signaling, Disease, and Emerging Therapeutic Modalities","volume":"169","author":"Nusse","year":"2017","journal-title":"Cell"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2008.04.014","article-title":"Wnt and Beyond Wnt: Multiple Mechanisms Control the Transcriptional Property of Beta-Catenin","volume":"20","author":"Jin","year":"2008","journal-title":"Cell Signal"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.15252\/embj.201488598","article-title":"Wnt Signaling Directs a Metabolic Program of Glycolysis and Angiogenesis in Colon Cancer","volume":"33","author":"Pate","year":"2014","journal-title":"EMBO J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13048-019-0596-z","article-title":"Wnt\/beta-Catenin Signalling in Ovarian Cancer: Insights Into its Hyperactivation and Function in Tumorigenesis","volume":"12","author":"Nguyen","year":"2019","journal-title":"J Ovarian Res"},{"key":"B16","article-title":"Beta-Catenin Regulates Vascular Endothelial Growth Factor Expression in Colon Cancer","volume":"63","author":"Easwaran","year":"2003","journal-title":"Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-012-0421-9","article-title":"Enhanced Nestin Expression and Small Blood Vessels in Human Pituitary Adenomas","volume":"16","author":"Perez-Millan","year":"2013","journal-title":"Pituitary"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1530\/endoabs.49.OC12.2","article-title":"Treatment of Aggressive Pituitary Tumours and Carcinomas: Results of a European Society of Endocrinology (ESE) Survey 2016","volume":"178","author":"McCormack","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11102-011-0341-0","article-title":"New Targeted Therapies in Pituitary Carcinoma Resistant to Temozolomide","volume":"15","author":"Jouanneau","year":"2012","journal-title":"Pituitary"},{"key":"B20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1080\/02688690500081230","article-title":"A Spectrum of Behaviour in Silent Corticotroph Pituitary Adenomas","volume":"19","author":"Baldeweg","year":"2005","journal-title":"Br J Neurosurg"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.14310\/horm.2002.1307","article-title":"Aggressive Silent Corticotroph Adenoma Progressing to Pituitary Carcinoma: The Role of Temozolomide Therapy","volume":"10","author":"Moshkin","year":"2011","journal-title":"Horm (Athens Greece)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.5137\/1019-5149.JTN.20216-17.1","article-title":"Course of Aggressive Somatotroph, Corticotroph and Mammotroph Tumors Under Temozolomide; Report of Three Cases and Review of the Literature","volume":"28","author":"Aydogan","year":"2017","journal-title":"Turkish Neurosurg"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21082831","article-title":"MSH6\/2 and PD-L1 Expressions Are Associated With Tumor Growth and Invasiveness in Silent Pituitary Adenoma Subtypes","volume":"21","author":"Uraki","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B24","article-title":"Galectin-3 as a Marker Distinguishing Functioning From Silent Corticotroph Adenomas","volume":"6","author":"Thodou","year":"2007","journal-title":"Horm (Athens Greece)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102980","article-title":"Distinct Pattern of Endoplasmic Reticulum Protein Processing and Extracellular Matrix Proteins in Functioning and Silent Corticotroph Pituitary Adenomas","volume":"12","author":"Eieland","year":"2020","journal-title":"Cancers"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2012.126","article-title":"Drugging Wnt Signalling in Cancer","volume":"31","author":"Polakis","year":"2012","journal-title":"EMBO J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"7329","DOI":"10.1038\/s41598-018-25672-6","article-title":"Dramatic Dysbalancing of the Wnt Pathway in Breast Cancers","volume":"8","author":"Koval","year":"2018","journal-title":"Sci Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2007.02620.x","article-title":"Prognostic Significance of the Wnt Signalling Pathway Molecules APC, Beta-Catenin and E-Cadherin in Colorectal Cancer: A Tissue Microarray-Based Analysis","volume":"50","author":"Lugli","year":"2007","journal-title":"Histopathology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.078642","article-title":"Wnt Signaling in Estrogen-Induced Lactotroph Proliferation","volume":"124","author":"Giles","year":"2011","journal-title":"J Cell Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-012-9197-8","article-title":"Expression and Clinical Significance of Wnt Players and Survivin in Pituitary Tumours","volume":"23","author":"Formosa","year":"2012","journal-title":"Endocr Pathol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2018.4355","article-title":"Decreased Expression of SFRP2 Promotes Development of the Pituitary Corticotroph Adenoma by Upregulating Wnt Signaling","volume":"52","author":"Ren","year":"2018","journal-title":"Int J Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1108275108","article-title":"Beta-Catenin Stimulates Pituitary Stem Cells to Form Aggressive Tumors","volume":"108","author":"Camper","year":"2011","journal-title":"Proc Natl Acad Sci United States Am"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-008-0147-x","article-title":"Pituitary Gland and Beta-Catenin Signaling: From Ontogeny to Oncogenesis","volume":"12","author":"Gueorguiev","year":"2009","journal-title":"Pituitary"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-004-4597-3","article-title":"Infrequent Mutation of APC, AXIN1, and GSK3B in Human Pituitary Adenomas With Abnormal Accumulation of CTNNB1","volume":"73","author":"Sun","year":"2005","journal-title":"J Neuro-oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2015.2862","article-title":"\u03b2-Catenin Knockdown Inhibits Pituitary Adenoma Cell Proliferation and Invasion via Interfering With AKT and Gelatinases Expression","volume":"46","author":"Zhao","year":"2015","journal-title":"Int J Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1673-5374.2012.04.008","article-title":"Effects of Fulvestrant on Biological Activity and Wnt Expression in Rat GH3 Cells","volume":"7","author":"Bai","year":"2012","journal-title":"Neural Regen Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1210\/en.2007-0542","article-title":"Wnt Pathway Inhibitors are Strongly Down-Regulated in Pituitary Tumors","volume":"149","author":"Elston","year":"2008","journal-title":"Endocrinology"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004580","article-title":"Cadherin-Bound \u00ce\u00b2-Catenin Feeds Into the Wnt Pathway Upon Adherens Junctions Dissociation: Evidence for an Intersection Between \u00ce\u00b2-Catenin Pools","volume":"4","author":"Kam","year":"2009","journal-title":"PloS One"},{"key":"B39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1042\/BJ20121284","article-title":"Wnt\/beta-Catenin Signalling: From Plasma Membrane to Nucleus","volume":"450","author":"Kim","year":"2013","journal-title":"Biochem J"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3233\/TUB-211500","article-title":"\u03b2-Catenin is Reduced in Membranes of Human Prolactinoma Cells and it is Inhibited by Temozolomide in Prolactin Secreting Tumor Models","author":"Demarchi","year":"2022","journal-title":"Tumor Biol"},{"key":"B41","article-title":"Participaci\u00f3n de las c\u00e9lulas madres en el desarrollo y progresi\u00f3n de los tumores hipofisiarios","author":"Demarchi","year":"2020"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010101)91:1<42::AID-CNCR6>3.0.CO;2-7","article-title":"Frequent Nuclear Accumulation of Beta-Catenin in Pituitary Adenoma","volume":"91","author":"Semba","year":"2001","journal-title":"Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"608497","DOI":"10.1155\/2014\/608497","article-title":"Angiogenesis in Pituitary Adenomas: Human Studies and New Mutant Mouse Models","volume":"2014","author":"Cristina","year":"2014","journal-title":"Int J Endocrinol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-010-9119-6","article-title":"VEGF and CD31 Association in Pituitary Adenomas","volume":"21","author":"Cristina","year":"2010","journal-title":"Endocr Pathol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1210\/en.2004-1445","article-title":"Increased Pituitary Vascular Endothelial Growth Factor-a in Dopaminergic D2 Receptor Knockout Female Mice","volume":"146","author":"Cristina","year":"2005","journal-title":"Endocrinology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"989574","DOI":"10.1155\/2014\/989574","article-title":"Correlations of Vascular Architecture and Angiogenesis With Pituitary Adenoma Histotype","volume":"2014","author":"Takano","year":"2014","journal-title":"Int J Endocrinol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1080\/08820530902805651","article-title":"Angiogenesis and Pituitary Tumors","volume":"24","author":"Cohen","year":"2009","journal-title":"Semin Ophthalmol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s12022-009-9057-3","article-title":"Invasive Giant Prolactinoma With Loss of Therapeutic Response to Cabergoline: Expression of Angiogenic Markers","volume":"20","author":"Mallea-Gil","year":"2009","journal-title":"Endocr Pathol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.576027","article-title":"Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy","volume":"11","author":"Lamb","year":"2020","journal-title":"Front Endocrinol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/BF02738884","article-title":"Vascular Endothelial Growth Factor (VEGF) Expression in Human Pituitary Adenomas and Carcinomas","volume":"10","author":"Lloyd","year":"1999","journal-title":"Endocr Pathol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00706","article-title":"Sex-Related Differences in Lactotroph Tumor Aggressiveness Are Associated With a Specific Gene-Expression Signature and Genome Instability","volume":"9","author":"Wierinckx","year":"2018","journal-title":"Front Endocrinol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s12020-020-02478-z","article-title":"The Role of the Tumour Microenvironment in the Angiogenesis of Pituitary Tumours","volume":"70","author":"Marques","year":"2020","journal-title":"Endocrine"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/BF03345118","article-title":"Microvascular Density and Vascular Endothelial Growth Factor Expression in Normal Pituitary Tissue and Pituitary Adenomas","volume":"26","author":"Viacava","year":"2003","journal-title":"J Endocrinol Invest"},{"key":"B54","doi-asserted-by":"publisher","first-page":"188356","DOI":"10.1016\/j.bbcan.2020.188356","article-title":"Fibrosis and Cancer: A Strained Relationship","volume":"1873","author":"Piersma","year":"2020","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.4103\/ajns.AJNS_16_20","article-title":"Decrease of Proliferative Potential and Vascular Density of Giant Prolactinoma in Patients Treated With Cabergoline","volume":"15","author":"Astaf'eva","year":"2020","journal-title":"Asian J Neurosurg"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1227\/NEU.0b013e318230ac63","article-title":"O-6-Methylguanine-DNA Methyltransferase (MGMT) Immunohistochemical Expression in Pituitary Corticotroph Adenomas","volume":"70","author":"Salehi","year":"2012","journal-title":"Neurosurgery"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-014-1702-0","article-title":"Temozolomide and Pasireotide Treatment for Aggressive Pituitary Adenoma: Expertise at a Tertiary Care Center","volume":"122","author":"Ceccato","year":"2015","journal-title":"J Neuro-oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.700007","article-title":"Clinical Efficacy of Temozolomide and Its Predictors in Aggressive Pituitary Tumors and Pituitary Carcinomas: A Systematic Review and Meta-Analysis","volume":"12","author":"Luo","year":"2021","journal-title":"Front Neurol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21217844","article-title":"Wnt-Independent and Wnt-Dependent Effects of APC Loss on the Chemotherapeutic Response","volume":"21","author":"Stefanski","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B60","doi-asserted-by":"publisher","first-page":"5378567","DOI":"10.1155\/2016\/5378567","article-title":"Overexpression of Beta-Catenin Induces Cisplatin Resistance in Oral Squamous Cell Carcinoma","volume":"2016","author":"Li","year":"2016","journal-title":"BioMed Res Int"},{"key":"B61","doi-asserted-by":"publisher","first-page":"8904","DOI":"10.1038\/ncomms9904","article-title":"Wnt\/beta-Catenin Pathway Regulates MGMT Gene Expression in Cancer and Inhibition of Wnt Signalling Prevents Chemoresistance","volume":"6","author":"Wickstrom","year":"2015","journal-title":"Nat Commun"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.870172\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T04:15:54Z","timestamp":1658204154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.870172\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,19]]},"references-count":61,"alternative-id":["10.3389\/fendo.2022.870172"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.870172","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,19]]},"article-number":"870172"}}